Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
about
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseasesCellular mediators of renal vascular dysfunction in hypertensionArachidonic acid cytochrome P450 epoxygenase pathwayReprogramming: A Preventive Strategy in Hypertension Focusing on the KidneyEpoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular functionRemoval of distal protein-water hydrogen bonds in a plant epoxide hydrolase increases catalytic turnover but decreases thermostabilityTargeting on Asymmetric Dimethylarginine-Related Nitric Oxide-Reactive Oxygen Species Imbalance to Reprogram the Development of HypertensionCyclooxygenase- and cytochrome P450-derived eicosanoids in strokeMammalian soluble epoxide hydrolase is identical to liver hepoxilin hydrolaseSoluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidneyA 3'-UTR Polymorphism in Soluble Epoxide Hydrolase Gene Is Associated with Acute Rejection in Renal Transplant RecipientsTargeting epoxides for organ damage in hypertensionRed blood cells (RBCs), epoxyeicosatrienoic acids (EETs) and adenosine triphosphate (ATP)Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammationSoluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertensionEpoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null miceAdenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARγEpoxides and soluble epoxide hydrolase in cardiovascular physiologyInhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine modelEffects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney diseaseDifferential action of bradykinin on intrarenal regional perfusion in the rat: waning effect in the cortex and major impact in the medulla.11,12-Epoxyeicosatrienoic acid induces vasodilator response in the rat perfused mesenteric vasculature.Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal diseaseBioactive lipid mediators in polycystic kidney diseaseProtein tyrosine phosphatase Shp2 deficiency in podocytes attenuates lipopolysaccharide-induced proteinuriaOxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse modelCombined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats.Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.The membrane and lipids as integral participants in signal transduction: lipid signal transduction for the non-lipid biochemist.Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis.Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARγInhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation.CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype.Expression and characterization of an epoxide hydrolase from Anopheles gambiae with high activity on epoxy fatty acids.Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actionsSoluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.20-Iodo-14,15-epoxyeicosa-8(Z)-enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14,15-epoxyeicosatrienoic acid receptorPharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.Eicosanoids, β-cell function, and diabetes
P2860
Q24597172-D1E02242-B7D8-4E13-A90F-2B7AAA383B62Q24644250-7751ADD8-695F-488C-8883-D007649574B3Q24653023-FA9249C9-12F4-4BB3-B47E-A17B037253B5Q26771815-CB700600-2BD6-48B6-B641-AC7E20F6887BQ26849271-D9CAA529-6F31-45D1-867F-25815B63F897Q27650731-EF75777D-FB48-470D-B499-73BCE0FB8B55Q28069733-BEFB4956-434B-4F48-ACFE-C66AC9741875Q28271874-857C2BCA-1BF1-49FE-B4EA-5F0B6829BFE6Q28302779-BA674CF9-C298-4226-90B7-7ECBE298E9F8Q28384279-AFF54975-8805-4B57-95BE-39E9CB9380FEQ28384776-95234CE4-3DBA-4C25-A117-797D41CCB579Q28387558-CB046EF8-FF9C-482D-9D24-624C4BA6AFB2Q28388012-11916597-E21A-4810-B154-188A86FD2CE9Q28389323-3AA9E1E9-C7A3-4B10-B467-12D8B23CCCE9Q28390972-95E53B49-F06C-4A74-BCD8-A326BC03D18CQ28392299-0CF0A79E-1156-4151-A164-C7B0D3B7925BQ28392991-2A2AC2C4-3936-48CD-9F57-553F52ACCA08Q28396313-F0BCB8D4-9125-4EA0-8F48-A6489B59AEA7Q28396881-C9128FED-4FA5-4515-BD16-9601E6FF32BBQ30658399-6DEE6B53-EE24-4008-90B4-F77B3F22CD37Q33467731-8AEA2CA4-FB59-4472-A0AB-1E91CB153558Q33578326-42E8AD9A-041E-48A3-99B7-1171B598D744Q33652488-E443493F-7A69-4C97-AB3F-2468636A0A03Q33653643-24F32394-B6C2-4CA9-9B3D-6C1DCD2FA403Q33673674-C40EF39D-85C2-4BCF-B844-B6CD97CAB436Q33714587-20D6C79F-A5A0-4A90-AC6C-9E6B2CA2B344Q33738489-B79E85F1-2C76-4E46-BC79-AE3BD0E4C899Q33787556-E0654249-D6CC-43D3-900D-162794361BCBQ33824220-A0190DC5-4182-4F80-8ACD-041722AA95B7Q34002685-75193327-534E-4B7A-8CF4-2974A653A1B3Q34035269-8A927A84-E097-4D31-AA3B-D269624B96C4Q34274294-07AB370A-8D3D-4FA4-9AB4-FC4B86219DB4Q34355908-8F4D2806-5685-4DE6-A859-B5A2E59E55E1Q34506020-BF17D093-5F10-4024-8EB4-2E7DD5D00BC7Q34616321-5F938A75-A31A-41FF-A36A-B58EE32F500AQ34691742-0E63664B-C5D1-480A-8581-1E4986BE76F5Q34783515-8E5AA4D9-0AA0-4E7B-9BB0-CACAD9A0F6B1Q34999553-72FCAE9E-1948-4279-9430-AD6248BA10B0Q35115765-3318E404-32E0-4D13-9909-5F8E65F259A8Q35129888-6E759653-69B3-4DD5-B95C-884640EF842E
P2860
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
@ast
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
@en
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
@nl
type
label
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
@ast
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
@en
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
@nl
prefLabel
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
@ast
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
@en
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
@nl
P2860
P1476
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.
@en
P2860
P304
P356
10.1152/AJPRENAL.00350.2004
P50
P577
2005-09-01T00:00:00Z